
Ajinomoto Co., Inc. First quarter-FY2014 Market and other information

1. Breakdown by Business Segment*1

(Billion Yen, figures in parenthesis represent YoY change)



^{*1} The following changes in accounting policies from FY2014.
Sales promotion discounts paid to customers to expand sales are deducted from net sales.
(Figures for FY2012 and subsequent fiscal years have been restated.)

2. Breakdown of Each Business Segment

Segment	Business	Main Brands/Products				
Domestic Food Products		Home use: AJI-NO-MOTO, HONDASHI, Cook Do, Knorr Cup Soup, Ajinomoto KK Consomme,				
		Pure Select Mayonnaise, various Gift sets				
	Seasonings and Processed	Restaurant and industrial use: seasonings and processed foods for restaurant use,				
	foods	Seasonings for processed food manufacturers*(savory seasonings, enzyme ACT/VA),				
		Delicatessens and Bakery products				
		*Overseas sales are included in domestic food products segment.				
	Frozen foods	Gyoza (Chinese dumpling), Yawaraka Wakadori Kara-Age (fried chicken), Ebi shumai (shrimp dumpling),				
	r 102en 100ds	Yoshokutei Hamburg (hamburg steak)				
Overseas Food Products		AJI-NO-MOTO (outside Japan), Ros Dee (flavor seasoning/Thailand), Masako (flavor seasoning/Indonesia),				
		Aji-ngon (flavor seasoning/Vietnam), Sazon (flavor seasoning/Brazil),				
	Consumer foods (mainly home use)	AMOY (Chinese ethnic sauce/Hong Kong), YumYum (instant noodles/Thailand),				
	(mainly nome use)	Birdy (coffee beverage/Thailand), Birdy 3in1 (powdered drink/Thailand),				
		CRISPY FRY (Menu-specificseasonings/Philippines)				
	Umami seasonings for	AJI-NO-MOTO and nucleotides for processed food manufacturers				
	processed food mfrs.	*Domestic sales are also included in overseas food products segment.				
Bioscience Products &	Feed-use amino acids	Lysine, Threonine, Tryptophan				
Fine Chemicals	Amino acids	Amino acids for pharmaceuticals and foods: Arginine, Glutamine, Valine				
		(ex. for infusion, for beverages)				
		Amino acid-based sweeteners: Aspartame, overseas retail sweetener products, PAL SWEET				
		Pharmaceutical Custom Manufacturing*2: anti-cancer drugs, auto immune disease, anti-AIDS drugs,				
		active ingredients for generics, natural extracts, etc.				
	Specialty chemicals	Cosmetic ingredients: Amisoft, Amilite (mild surfactant), Ajidew (humectant)				
		Cosmetics: Jino				
		Electronic materials: ABF (insulation film for build-up printed wiring board)				
Pharmaceuticals	Prescription drugs	Prescription drugs*1: Gastrointestinal diseases (LIVACT, ELENTAL,MOVIPREP),				
	Prescription drugs	Metabolic diseases, etc. (ATELEC, FASTIC, ACTONEL, ATEDIO)				
Other Business	-	Wellness: Fundamental foods (Glyna, Capsiate Natura), Functional foods (amino VITAL),				
		Medical foods (MEDIF, IMPACT)				
		Other: Logistics, Edible oils & Coffee products, Service, others				

^{*1} On July 1, 2013, AJINOMOTO PHARMACEUTICALS CO., LTD. spins off infusion and dialysis products (SOLITA-T, PNTWIN, etc.) into AY PHARMACEUTICALS CO., LTD.

3. Domestic Food Products

(Dillion Von)

(1) Market snare and position of main brands in the Japanese nousehold market (Ajinomoto estimate).							
		FY2012		FY2013		FY2014	
Category	Brands	Market	Ajinomoto's %(rank)	Market	Ajinomoto's %(rank)	Market (est.)	
Umami seasonings	AJI-NO-MOTO, Hi-Me	6.9	93%(1)	6.9	92%(1)	6.3	
Japanese flavor seasonings	HONDASHI	40.2	56%(1)	41.9	57%(1)	41.1	
Consomme	Ajinomoto KK Consomme	12.7	66%(1)	12.5	65%(1)	12.5	
Soup	Knorr	83.5	38%(1)	86.2	37%(1)	87.4	
Mayonnaise and mayonnaise-type dressings	Pure Select	48.1	28%(2)	48.0	28%(2)	46.2	
Menu seasonings	Cook Do Cook Do Kyo-no Ohzara	77.3	26%(1)	78.6	28%(1)	79.4	

Figures have changed due to revision of data.

(2) Ratio of sales for home use/restaurant and industrial use (Billion Yen) FY2012 1Q-FY2013 FY2013 1Q-FY2014 195.7 44.3 196.2 Seasonings Sales Home use*2 54% 50% 53% 49% and Processed foods' Restaurant and institutional use*3 46% 50% 51% 47% Sales for Japanese market*4 27.5 28.2 110.0 112.4 Frozen foods 63% 64% 62% 62% Restaurant and institutional use 37% 36% 38% 38%

4. Overseas Food Products

Estimated demand for MSG and nucleotides

(Thousand MT)

	FY2012					FY	2013	,
	China	Other	Total	Ajinomoto's %	China	Other	Total	Ajinomoto's %
MSG	1,500	1,380	2,880 *1	approx.20%	1,540	1,420	2,960 *2	approx.20%
Nucleotides	-	-	34	approx.35%	-	-	37	approx.30%

^{*1} retail: a little under 60%, industrial use: a little over 40%

5. Bioscience Products & Fine Chemicals

(1) Market price and estimated market size of feed-use amino acids

		FY2011	FY2012	1Q-FY2013	FY2013	1Q-FY2014	1H-FY2014	FY2014
		F12011	F12012	10-112013	F12013	1Q-F12014	(est.)*2	(est.)*2
Spread (US\$/ST)*1		95	190	195	255	310	approx. 300	approx. 200
Market Price	Lysine	2.35	2.15	1.75	1.60	1.30	approx. 1.35	approx. 1.45
(US\$/kg,	Threonine	2.45	2.30	2.20	2.05	2.00	approx. 2.10	approx. 2.10
CIF main port basis)	Tryptophan	15	17	16	15	15	approx. 16	approx. 16
	Lysine	1,700	1,950	/	2,100			approx. 2,200
	Ajinomoto's%	approx. 20%	approx. 20%		15-20%			approx. 15%
Market size	Threonine	270	330		400			approx. 430
(Thousand MT)	Ajinomoto's%	approx. 30%	approx. 30%		approx. 30%			approx. 30%
	Tryptophan	6	9		14			approx. 20
	Ajinomoto's%	approx. 40%	approx. 45%		approx. 35%	/		approx. 25%

^{*1} The price difference between soybean meal and corn on the Chicago Board of Trade (CBOT)

(2) Estimated market size of amino acid-based sweetener, aspartame

(2) Estimated market size of amino acid-based sweetener, aspartame									
	FY2012		FY2013		FY2014(est.)				
	Market	Ajinomoto's%	Market	Ajinomoto's%	Market	Ajinomoto's%			
Aspartame (Thousand MT)	approx.24.5	approx.30%	approx.25.0	approx.30%	approx.25.0	approx.30%			

6. Pharmaceuticals

(1) Sales* of main products (AJINOMOTO PHARMACUETICALS CO., LTD. estimate)

(Billion Yen)

			COL TIONES CO., ETD. Colimato)				Dillion Toni
Field	Main Products	Launch Date	Indication or Formulation	Marketing Company	FY2013	Q1-2014	Y/Y %
	LIVACT	May 1996	Amino acid formula for treatment of liver cirrhosis	AJINOMOTO PHARMACUETICALS CO., LTD.	14.8	3.5	94%
Gastro-	ELENTAL	Sept. 1981	Elemental diet	AJINOMOTO PHARMACUETICALS CO., LTD.	7.7	1.9	98%
intestinal	MARZUREN	July 2012	Antigastritis and anti-ulcer drugs	AJINOMOTO PHARMACUETICALS CO., LTD.	3.5	0.8	84%
diseases	MOVIPREP	June 2013	Bowel preparation prior to colonoscopy and colon surgery	AJINOMOTO PHARMACUETICALS CO., LTD.	0.8	0.5	1113%
	NIFLEC	June 1992	Oral cleaning solution for the intestine	AJINOMOTO PHARMACUETICALS CO., LTD.	2.2	0.4	71%
	HEPAN ED	Sept. 1991	Elemental	AJINOMOTO PHARMACUETICALS CO., LTD.	0.9	0.2	90%
Metabolic	ATELEC	Dec. 1995	Long-acting calcium channel blocker	Mochida Pharmaceutical Co., Ltd.	14.6	3.2	84%
	ACTONEL	May 2002	Osteoporosis treatment	Eisai Co., Ltd.	10.0	2.2	86%
deseases, etc.	FASTIC	Aug. 1999	Fast-acting postprandial antihypoglycemic agent	Mochida Pharmaceutical Co., Ltd.	1.8	0.4	75%
GIU.	ATEDIO		selective AT1 receptor blocker/long-acting calcium antagonist	Mochida Pharmaceutical Co., Ltd.	-	0.3	-

NHI (National Health Insurance) reimbursement price basis. Effect of NHI drug price revision implemented: April 2014 approx.-6%

^{*} Consumer purchase basis

^{*1} Previous years' figures for Kellogg's products restated as net sales less cost of sales.

^{*2} Restaurant and industrial use includes seasonings & processed foods for restaurant use, seasonings for processed food manufacturers, delicatessens and bakery products.

^{*3} Home use includes seasonings & processed foods for home use and gift set.

^{*4} Sales for Japanese market are total sales.

^{*2} retail: a little under 60%, industrial use: a little over 40%

^{*2} Spread and market prices do not correspond with assumptions in Ajinomoto's forecast of results.

(2) Development Pipeline July, 2014

	Name	Development Status	Indication	Note
Gastrointestinal diseases	AJG511	Phase II	Ulcerative colitis	In-license (Dr. Falk Pharma)
	AJM300	Phase II	Ulcerative colitis	
	FASTIC	NDA	Type / Diapetes Mellitus	Combination therapy with DPP-4 inhibitor

(3) Newly Launched Products after July, 2013 July, 2014

Field	Name	Launch	Indication or Classification	Note
Gastrointestinal diseases	LIVACT	July, 2013		Additional formulation / Jellies for oral administration
Metabolic diseases	ATELEC	December, 2013	Hypertension	Additional formulation / 20mg Tablet
ivietabolic diseases	ATEDIO	May, 2014	Hypertension	Valsartan/Cilnidipine combination tablet

Note: This includes forward-looking statements based on a number of assumptions.

Actual results may differ substantially depending on a number of factors including but not limited to economic trends and exchange rates.

Amounts presented in this material are rounded off.